Christopher Anzalone, Arrowhead Pharmaceuticals CEO
Vivo Capital pitches $60M to bring Arrowhead's RNAi meds to China via joint venture
Generally speaking, any biotech hoping to have a presence in China has a number of options.
One could out-license its drugs to one of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
